Easy to use and minimal training
One year warranty
Run up to 6 COVID-19 2SF tests
in about two hours
Ships within two days
*Must be a CLIA-certified high-complexity laboratory as outlined under the FDA's Emergency Use Authorization requirements.
At this time, only serving the midwest states of Nebraska, Iowa, Kansas, South Dakota and North Dakota.
Cassling is honored to partner with MatMaCorp, a Nebraska-based company, to provide an affordable solution to supplement the COVID-19 testing at your facility.
The Solas8® device, along with the MatMaCorp COVID-19 2SF Test, is designed for rapid detection of SARS-CoV-2 RNA for the diagnosis of COVID-19.
Questions? Call customer support at 402-387-7900.
*Based on in silico analysis, the primers/probe in the MatMaCorp COVID-19 2SF Test may cross-react with SARS-CoV and cause a false-positive result. This coronavirus is not known to currently circulate in the human population.
|MatMaCorp COVID-19 2SF Test||100 reactions||$3,000|
“The MatMaCorp COVID-19 2SF test has enabled us to support our staff and community with testing during the pandemic by providing an on-site solution for workers and patients.
With this, we are able to make sure our facility is able to maintain staffing and provide patients with care more quickly.
We really like that there is no contract or minimum orders, and their on-site training program and continued support have made it easy to integrate into our lab.”
--Tori Seberger, Laboratory Information System Coordinator, Kearney Regional Medical Center, Kearney, Nebraska
Click the button below to be taken to our order form, then simply select the number of devices and testing kits you'd like to order.
Disclaimer: This test has not been FDA cleared or approved but has been authorized for emergency use by FDA under an EUA for use by authorized laboratories; This test has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens; and The emergency use of this test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.